Viral and symptom rebound following anti-SARS-CoV-2 monoclonal antibody therapy in a randomized placebo-controlled trial

By sjmartinez • October 15, 2024

Chew KW, McGinley B, Moser C, Li JZ, Evering TH, Ritz J, Javan AC, Margolis D, Wohl DA, Hughes MD, Daar ES, Currier JS, Eron JJ, Smith DM; ACTIV-2/A5401 Study Team. Viral and symptom rebound following anti-SARS-CoV-2 monoclonal antibody therapy in a randomized placebo-controlled trial. J Infect Dis. 2024 Oct 14:jiae501. doi: 10.1093/infdis/jiae501. Epub ahead of print. PMID: 39400063.

Tags: covid-19, COVID-19 treatment, Harbor UCLA, Infectious Diseases, Monoclonal antibodies, non-hospitalized adults, Publications, SARS-CoV-2, symptom rebound, viral rebound

Related Posts

Advancing Equitable Kidney Care through Population Health Approaches in Los Angeles County’s Safety Net System

Kalantar-Zadeh K, Raff EA, Chong CC, Yang JK, Le TK, Barba LM, Pham PC, Dhamija R, Ghaffari A, Khine A, Patel N, Nicholas SB, Sim[...]

Prevalence and Outcomes of Chronic Kidney Disease-Associated Pruritus: International Results from Peritoneal Dialysis Outcomes and Practice Patterns Study

Tennankore KK, McCullough K, Bieber B, Cho Y, Johnson DW, Kanjanabuch T, Kawanishi H, Kim YL, Lambie M, Rigatto C, Shen J, Schreiber M, Perl[...]

A Review of Photon-Counting Computed Tomography (PCCT) in the Diagnosis of Cardiovascular Diseases

Sharma A, Cerdas MG, Reza-Soltani S, Rustagi V, Guntipalli M, Rojas Torres DS, Bhandari M, Kandel S, Teja Rayaprolu D, Hussain M. A Review of[...]